This coauthored review surveys reported aerospace and undersea phenomena, historical cases and proposed research. Selected figure pages distinguish drawings, photographs, material reports and hypothetical interpretations. Its coauthors and reproduced cases do not supply independent verification of underlying events, anomalous materials or government programmes.
Prior supplied HTML; all 195 retained native layouts viewedThis HCA perspective, coauthored by Garry Nolan, describes equitable participation, local research leadership, informed consent, privacy and open versus managed data access. Its claims concern consortium aims and reported activities, rather than a clinical trial or proof of universal benefits. Public scientific collaboration and institutional affiliations do not demonstrate a secret government approach or UAP programme.
Complete supplied XML text; original figure pixels unreviewedThis observational human-tissue study associates distinct macrophage populations with different colon-cancer outcomes: IL4I1 with favorable survival in two reported cohorts and SPP1 with unfavorable survival in one. Nested cells and tissue regions are not independent patients; no adjusted or prospectively validated clinical predictor is established. A reused breast-cancer treatment-response measure is T-cell receptor expansion, a surrogate. Nolan is a Resources coauthor. Public cancer-research grants name other recipients and establish no classified approach or UAP programme. Figures and supplements remain unreviewed.
Complete specialist supplied XML text; native graphics unreviewedThis lymphoma study maps T-cell composition across 101 lymph-node samples and imaging specimens from 19 patients. Cells, cores and repeated assays remain dependent. External cohorts associate signatures with survival, but thresholds are data-derived and endpoint wording conflicts remain. Spatial proximity and inferred trajectories do not establish mechanism or clinical accuracy. Nolan contributes resources, supervision and funding acquisition; commercial roles and research support do not establish a classified UAP approach.
Complete specialist supplied XML text; native apparatus unreviewedMAPS uses expert-labelled protein-expression data to classify cells. The authors report strong results within datasets, while acknowledging leakage risk from splitting one patient’s CODEX image by cells. Performance falls across cohorts and competing methods sometimes do better. Nolan is a coauthor and supervisor; disclosed commercial interests, reporting differences and missing original materials accompany the findings.
Complete supplied article and supplement text read; original and tiny-label gapsThe 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.
Partial root native PDF text and selected layout reviewThis Nolan-coauthored study introduces MaxFuse, a computational method for aligning cell measurements across weakly linked data types. Benchmarks report gains on selected datasets; inferred spatial gene activity is distinguished from measurements actually made in each cell. Reused cell batches and tuned comparisons limit broader conclusions. The article explicitly attributes FDA Medical Countermeasures Initiative contracts and NIH support to Nolan, without reporting a secret approach or classified UAP programme.
Complete supplied XML text; original figures and supplements unreviewedThis healthy-adult intestine atlas describes regional tissue composition and spatial organization in nine donors. Millions of cells and regional sections remain nested within donors. Predicted signalling and regulatory associations are hypotheses; subset validation overlaps one donor and does not establish a clinical or causal mechanism. Nolan is a corresponding coauthor and supervisor. Published funding and commercial disclosures provide ordinary research context, without establishing a classified approach or UAP programme.
Complete specialist supplied XML text; native apparatus unreviewedThis proof-of-concept study introduces ExPRESSO for higher-resolution imaging of archived tissue on existing mass-spectrometry platforms. The reported lateral enlargement is about 3.7-fold, with axial compression, edge distortion and marker-specific signal limits. Alzheimer’s examples use six individuals, not hundreds of patients; vessel counts and image fields are nested observations. Nolan’s disclosed FDA funding and instrument-company interests are explicit. The study does not report UAP patients, a secret government approach or a clinical diagnostic trial.
Complete supplied XML text; original figures and supplements unreviewedThis leukemia paper reports laboratory, mouse and limited human-sample findings. The primary-sample combination result at 48 hours does not improve apoptosis beyond steroid alone; longer-culture observations use two selected specimens. Mouse survival findings require qualification for unequal toxicity censoring. It does not establish human combination-treatment efficacy. Nolan is credited with resources and clinical data alongside a coauthor, without a named funding award or government/UAP approach in this article.
Partial specialist supplied XML; method section and apparatus unreviewedThis observational ulcerative-colitis atlas describes tissue organization in29patients and five controls. Cells and regions remain nested within individuals. Cross-sectional treatment and sex associations do not establish a resistance mechanism, and19-patient response prediction was unstable and nonsignificant. Nolan is a coauthor with published funding and commercial interests, not a corresponding author. These ordinary scientific attributions supply no classified approach or UAP programme evidence.
Complete root supplied XML text; native apparatus unreviewedRobert Orr’s FDA presentation publicly describes a 2017 modification of contract HHSF223201610018C and links 75F40120C00176 to a collaboration studying COVID-19 illness in diverse populations. These identifiers match contracts acknowledged for Nolan in MaxFuse. The slides document agency statements about public research funding; they do not name Nolan or establish secret invitations or UAP access.
Partial root native PDF text and selected layout reviewA curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach